Can a cancer pill boost CAR T-Cell power against leukemia?
NCT ID NCT05993949
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This early-phase study tests whether adding pulses of the cancer drug dasatinib can improve CAR T-cell therapy (brexucabtagene autoleucel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants will receive dasatinib on a weekly 3-day schedule for up to 3 months after their CAR T-cell infusion. The main goal is to see if this drug schedule is practical and safe, not yet to measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Palo Alto, California, 94305, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brexucabtagene autoleucel (CAR T-cell therapy) plus dasatinib (a cancer drug)
What this could lead to
If this combination works, it could make CAR T-cell therapy safer and more effective for people with hard-to-treat leukemia.
What could go wrong
This is a very early, small study with only 8 participants. The main goal is just to see if the drug schedule is feasible, not to prove it works. Side effects from dasatinib or the cell therapy are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.